成人激情av,桃子视频,欧美成人性爱视频,国产精品久久久爽爽爽麻豆色哟哟,深度开发1v3笔趣阁,射精视频在线观看,色综合久久天天综合网,欧美久草,国产97伦理,天堂黄色电影网,女优在线播放一区

加入收藏 | 設(shè)為首頁 | 聯(lián)系我們

產(chǎn)品搜索

聯(lián)系我們

聯(lián)系人：蔣經(jīng)理
電話：4008750250
號碼：
手機：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com

產(chǎn)品展示 / PRODUCTS
藥靶細胞株 > kinase激酶細胞株 > CBP73196KIF5B（E15）-RET（E12） V804M/BaF3

KIF5B（E15）-RET（E12） V804M/BaF3
名稱 KIF5B（E15）-RET（E12） V804M/BaF3
型號 CBP73196
報價
特點 KIF5B（E15）-RET（E12） [V804M]/BaF3,母細胞：BaF3，凍存條件：90% FBS+10% DMSO
  • 詳細內(nèi)容
CBP73196
I. Introduction

Cell Line Name：

KIF5B(E15)-RET(E12) [V804M]/BaF3

Host Cell:

BA/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RRPMI-1640+10%FBS

Mycoplasma Status:

Negative


II.Background

Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC). These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468. They are typically identified in young patients with adenocarcinoma histology and minimal smoking history. Therapeutic targeting of RET-fusion–driven NSCLCs has taken the form of treatment with broad-spectrum tyrosine kinase inhibitors with anti-RET activity, such as cabozantinib (Cabometyx; Cometriq), vandetanib (Caprelsa), lenvatinib (Lenvima), RXDX-105, and sunitinib (Sutent). Cabozantinib and vandetanib have been the most heavily studied multi-kinase inhibitors (MKIs), with response rates of 20% to 50% in largely pretreated patients with RET-rearranged NSCLC. Sunitinib has been used in fewer patients to date with initial results demonstrating a 22% response rate. RXDX-105 has exhibited uniquely impressive response rates (75%) in patients with non–KIF5B-RET-fusion NSCLC, compared with 0% response in patients with KIF5B-RET-fusion–positive NSCLC. BLU-667 has demonstrated an objective response rate of 50% in patients with RET-fusion positive NSCLC, and LOXO-292 reported a 74% ORR in patients with RET-fusion positive NSCLC. Notably, RXDX-105, BLU- 667, and LOXO-292 have all demonstrated some central nervous system activity in these early phase trials. Future directions of RET inhibition in patients with RET-rearranged NSCLC include additional clinical validation of the next generation RET-selective inhibitors RXDX-105, BLU-667, and LOXO-292 and comparing multikinase inhibitors with RET-selective inhibitors to determine the optimal sequencing of RET-targeted therapies.


III. Representative Data

1. WB of  KIF5B-RET [V804M]/BaF3

CBP73196 WB.png


2. Sanger of KIF5B-RET [V804M]/BaF3

CBP73196 sanger1.png

CBP73196 sanger2.png


3. Anti-proliferation assay


CBP73196 fig.jpg

Figure 4. CTG Proliferation Assay of BaF3 KIF5B-Ret(S) V804M Cells (C1).




如果你對CBP73196KIF5B（E15）-RET（E12） V804M/BaF3感興趣，想了解更詳細的產(chǎn)品信息，填寫下表直接與廠家聯(lián)系：


留言框

  • 產(chǎn)品：

  • 您的單位：

  • 您的姓名：

  • 聯(lián)系電話：

  • 常用郵箱：

  • 省份：

  • 詳細地址：

  • 補充說明：

  • 驗證碼：

    請輸入計算結(jié)果（填寫阿拉伯?dāng)?shù)字），如：三加四=7

化工儀器網(wǎng)

推薦收藏該企業(yè)網(wǎng)站
桃色插| 熟女少妇尤物17c| 4433淫乱| 精品熟女少妇一区二区三区| 人妻、熟女、熟妇| 泰国无码精品| 查看中日韩操逼视频播放| 人 人 人 操| 本地伊人老太太乱伦性爱中国| 操屄视频在线播放| 在线播放无码后入内射少妇| 国产亚洲性爱自拍| 色图自拍偷拍| 乱伦黄色小说视频| gay黄色网址| 亚洲日韩中文天堂在线视频| 人人草人人爽人人曰| 女人爽到高潮潮久久久| 88av88 强奸| caocao综合| 在线观看亚洲成人视频| 999精品中文乱| 大香蕉碰碰欧美| FreeXXX国产天美传媒| CaoPorn超碰cao| 婷婷在线视频| 久久久免费性爱视频| 日韩125页| 初撮人妻五十路| 精品一区精品二区| 亚洲第一页第二页| 亚欧免费高清av| 精品无码91鲁大师| 两个东北小伙在部队里的生活| 色窝窝影视| 日p在线在线| jskajoqjo黄色视频| 蜜芽在线精品| 色色色色色色色色色色色色色色91 | 欧美中文妻| 久久综合97色|